ŌGI Bio

Executive Summary

ŌGI Bio is a UK-based synthetic biology company (founded 2019) that has developed the OGI3 Bioreactor, an automated, modular bench-top system designed to replace manual shake-flask methods for microbial development. The platform accelerates R&D for bacteria, yeast, and algae by providing scalable, high-quality data, improving reproducibility and efficiency. With a focus on simplifying workflows, ŌGI Bio targets the growing demand for automation in microbiome and synthetic biology research. The company is privately held and based in London, with no disclosed funding or valuation, but its innovative approach positions it to capture market share in the bioprocessing tools sector. While early-stage, the platform's potential to reduce time-to-insight for researchers could drive adoption across academic and industrial labs.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation OGI3 Bioreactor with enhanced throughput or AI integration60% success
• H2 2026Strategic partnership with a major pharma or CRO for process development50% success
• Q2 2026Series A funding round led by top-tier life science VCs40% success